{"id":"NCT02831660","sponsor":"Boehringer Ingelheim","briefTitle":"CU Programme of Idarucizumab for Japanese Patients","officialTitle":"A Compassionate Use Program of Idarucizumab for Reversal of the Anticoagulant Effects of Dabigatran in Japanese Patients Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-22","primaryCompletion":"2016-09-16","completion":"2016-09-16","firstPosted":"2016-07-13","resultsPosted":"2018-03-20","lastUpdate":"2018-03-20"},"enrollment":1,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemorrhage"],"interventions":[{"type":"DRUG","name":"idarucizumab","otherNames":[]}],"arms":[{"label":"idarucizumab","type":"EXPERIMENTAL"}],"summary":"The objective is to collect the safety data of idarucizumab for patients treated with dabigatran who require rapid reversal of the anticoagulant effects of dabigatran in cases of uncontrolled or life-threatening bleeding or when emergency surgery or urgent procedures are required.","primaryOutcome":{"measure":"Percentage of Subjects With Drug-related Adverse Events","timeFrame":"from first drug administration until 5 days after last drug administration, up to 6 days.","effectByArm":[{"arm":"Idarucizumab 5 g","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":1},"commonTop":["Platelet count decreased"]}}